Exenatide
moderate riskAlso: Byetta · Bydureon BCise · Exendin-4
Exenatide (Exendin-4) was the first FDA-approved GLP-1 receptor agonist, derived from Gila monster venom (Heloderma suspectum). 53% sequence homology with human GLP-1 leads to higher immunogenicity than later agents. Historically significant; clinically superseded.
Reported Benefits
Glycemic control
HbA1c reduction 0.8–1.1%; FDA approved since 2005.
Weight loss
~3–4% weight loss — less than all subsequent GLP-1 agents.
Mechanism of Action
GLP-1 receptor partial agonist; DPP-4 resistant; stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying.
Key Clinical Studies
DeFronzo et al. (2005)
Phase III RCT · n=733
HbA1c -0.9% at 30 weeks; first GLP-1 agonist FDA approval
Historical Importance
Exenatide proved the GLP-1 receptor agonist class in humans. The Gila monster origin story remains memorable. It has been superseded in efficacy by every subsequent GLP-1 agent, but biosimilars are making it relevant again as a cost-effective alternative.
Regulatory Status
FDA ApprovedFDA approved — Byetta (twice daily), Bydureon (weekly ER)
Safety Profile
Side Effects
- •Nausea
- •Vomiting
- •Immunogenicity
- •Pancreatitis (rare)
- •Injection site nodules (Bydureon)
Contraindications
- •T1D
- •Severe renal impairment
- •MTC/MEN2 history
Drug Interactions
- •Warfarin
- •Sulfonylureas
- •Oral medications
Primary Uses
Related Peptides
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe Exenatide?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →